Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

LEXINGTON, MA--(Marketwired - May 17, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...
May 15, 2017 07:30 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results

LEXINGTON, MA--(Marketwired - May 15, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...
May 08, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results

LEXINGTON, MA--(Marketwired - May 8, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of...
April 27, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial

LEXINGTON, MA--(Marketwired - Apr 27, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation,...
April 20, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome

LEXINGTON, MA--(Marketwired - Apr 20, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous...
April 18, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial

LEXINGTON, MA--(Marketwired - Apr 18, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation,...
March 30, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Reports Full Year 2016 Financial Results

LEXINGTON, MA--(Marketwired - Mar 30, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation,...
March 22, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results

LEXINGTON, MA--(Marketwired - Mar 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...
February 28, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

LEXINGTON, MA--(Marketwired - Feb 28, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...
February 22, 2017 08:00 ET | Source: Aldeyra Therapeutics

Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome

LEXINGTON, MA--(Marketwired - Feb 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to...